AN2 Therapeutics

AN2 Therapeutics

AN2 Therapeutics

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

2018ActiveMenlo Park, United States
Rate

About

AN2 Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with programs focused on targets in oncology and infectious diseases.

Signals agent

Reach companies that have budget right now

Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.

  • Just raised a roundFresh budget, the week it lands
  • Hiring sales and marketingGo-to-market roles mean money to spend
  • Hiring fastA jump in open roles across the company
  • In the newsLaunches and announcements worth a message
  • The decision makerWho to contact, with a message you can edit

Is your startup an alternative to AN2 Therapeutics?

People comparing tools land here. Get listed beside these.

Copy AN2 Therapeutics's SEO strategy

How often they publish, which searches their posts chase and their newest posts. Then outrank them.

All funding rounds

Key facts

Website
an2therapeutics.com
Headquarters
Menlo Park, United States
Founded
2018
Founders
George H. Talbot, Joseph S. Zakrzewski, Eric Easom, Michael R.K. Alley
Total funding
$132M (Private Placement)
Business model
B2B

Funding rounds

Funding rounds raised by AN2 Therapeutics
DateRoundAmountLead investors
9 Mar 2026Private Placement$40M
7 Jan 2022Series B$80M
21 Nov 2019Series A$12M

Tech stack

Detected on an2therapeutics.com, last scanned 13 Nov 2026.

Frontend
jQuery, Bootstrap
Analytics
Google Analytics 4
SEO
Yoast SEO
CMS / Builders
WordPress
CDN
Cloudflare
Cookie consent
Cookiebot

Benchmarking

See how your site ranks against 16,849 startups

AN2 Therapeutics sits in the 39th percentile for Domain Rating. Check where yours lands, free.

AN2 Therapeutics has a Domain Rating of 31, the 39th percentile of 16,849 startups we track.

Scores

Measured, not editorial

31

Measured by AhrefsAhrefs DR

Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.

Below median

Check yours
62

Measured by StartupHub.aiAgent Readiness

How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.

Top 25%

Scan yours
63

Measured by Google PageSpeedSite Speed

Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.

Above median

PageSpeed
80

Measured by StartupHub.aiData Trust

Whether this company is a safe place to put your data: security posture, privacy signals, and reputation evidence we could verify.

Top 25%

Measured by StartupHub.aiSecurity

What this company’s API or MCP server gives an anonymous stranger: transport, whether anything answers without credentials, CORS, response headers and, when an MCP server replies, which of its tools can be called with no key. Scanned live, on request, because a security verdict months old is worse than none.

Click to scan

Agent Readiness

Can AI agents use your site?

AN2 Therapeutics scores 62. Check yours free in a few seconds, or let Max Agent rerun it daily.

Run it daily with Max Agent
Median 41Across 23,755 scanned sites

Get notified when AN2 Therapeutics changes

Used AN2 Therapeutics? Write a review and get $5 in credits

Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:

  • Email finder
  • Market Map Maker
  • Agent Readiness scans
  • Deep intel
  • Tech stack scans

Frequently asked

Is AN2 Therapeutics growing?

Yes, fast. Our data shows it raised $40M in a Private Placement in March 2026.

Who owns AN2 Therapeutics?

AN2 Therapeutics is privately held, owned by its founders and investors. Investors on record include Citadel. Exact stakes are not public.

Are there companies like AN2 Therapeutics?

Yes. We list 9 companies like AN2 Therapeutics, including Juno Therapeutics, Jazz Pharmaceuticals and Moderna.

What does AN2 Therapeutics do?

They are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.

Is AN2 Therapeutics trustworthy and reputable?

StartupHub's Data Trust & Reputation score for AN2 Therapeutics is 80 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has AN2 Therapeutics raised?

AN2 Therapeutics has raised a total of $132M in funding. The most recent round on record is Private Placement.

SEC filings, insider activity, nonprofit links and pay benchmarks for AN2 Therapeutics:

Company details: from public sources. Funding: 3 rounds on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules

Categories

Need more than this profile? Deep intel researches any company website: team, funding, customers and tech.

Max Agent

Let Max Agent watch AN2 Therapeutics and its market for you

New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.

Free week

Starter listings, once

AI answers checked

Daily for 7 days

  • ChatGPT
  • Perplexity

Max Agent

$79 a month, or $9.99 with our badge on your site

AI answers checked

Every week

  • ChatGPT
  • Claude
  • Perplexity
  • Gemini